Damora Therapeutics (DMRA) Net Income towards Common Stockholders (2019 - 2026)

Damora Therapeutics' Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$27.8 million for Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 996.84% year-over-year to -$27.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$231.2 million (down 1150.22% YoY) and the FY2025 annual result came in at -$206.0 million, down 860.77% from the prior year.
• Net Income towards Common Stockholders was -$27.8 million for Q1 2026 at Damora Therapeutics, up from -$196.9 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $1.7 million in Q4 2023 and bottomed at -$196.9 million in Q4 2025.
• A 5-year average of -$20.5 million and a median of -$8.1 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders surged 112.19% — and 2025, when it plunged 2820.58%.
• Damora Therapeutics' Net Income towards Common Stockholders stood at -$13.7 million in 2022, then jumped by 112.19% to $1.7 million in 2023, then plunged by 504.38% to -$6.7 million in 2024, then plunged by 2820.58% to -$196.9 million in 2025, then surged by 85.89% to -$27.8 million in 2026.
• Business Quant data shows DMRA's Net Income towards Common Stockholders at -$27.8 million in Q1 2026, -$196.9 million in Q4 2025, and -$3.1 million in Q3 2025.